1. Home
  2. NG vs PBLS Comparison

NG vs PBLS Comparison

Compare NG & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novagold Resources Inc.

NG

Novagold Resources Inc.

HOLD

Current Price

$5.93

Market Cap

4.0B

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$31.28

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NG
PBLS
Founded
1984
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.6B
IPO Year
2002
2026

Fundamental Metrics

Financial Performance
Metric
NG
PBLS
Price
$5.93
$31.28
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$12.22
N/A
AVG Volume (30 Days)
5.5M
502.7K
Earning Date
04-01-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.07
$25.56
52 Week High
$14.40
$33.65

Technical Indicators

Market Signals
Indicator
NG
PBLS
Relative Strength Index (RSI) 44.56 56.52
Support Level $5.08 $26.83
Resistance Level $6.64 $33.65
Average True Range (ATR) 0.32 2.62
MACD 0.09 0.14
Stochastic Oscillator 54.22 63.76

Price Performance

Historical Comparison
NG
PBLS

About NG Novagold Resources Inc.

Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: